AstraZeneca PLC (AZN)vsBoston Scientific Corp (BSX)
AZN
AstraZeneca PLC
$185.48
-0.59%
HEALTHCARE · Cap: $293.73B
BSX
Boston Scientific Corp
$44.23
-2.06%
HEALTHCARE · Cap: $60.84B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 196% more annual revenue ($62.38B vs $21.07B). AZN leads profitability with a 17.7% profit margin vs 16.6%. BSX appears more attractively valued with a PEG of 0.63. AZN earns a higher WallStSmart Score of 68/100 (B-).
AZN
Strong Buy68
out of 100
Grade: B-
BSX
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.3%
Fair Value
$197.94
Current Price
$185.48
$12.46 discount
Margin of Safety
-9.2%
Fair Value
$39.15
Current Price
$44.23
$5.08 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 29.6%
Earnings expanding 23.5% YoY
Generating 4.0B in free cash flow
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 20.2%
Areas to Watch
Moderate valuation
Distress zone — elevated risk
1.4% revenue growth
Distress zone — elevated risk
Earnings declined 21.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 29.6%. PEG of 1.35 suggests the stock is reasonably priced for its growth.
Bull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 16.6% and operating margin at 20.2%. PEG of 0.63 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : BSX
The primary concerns for BSX are Revenue Growth, Altman Z-Score, EPS Growth.
Key Dynamics to Monitor
AZN profiles as a mature stock while BSX is a value play — different risk/reward profiles.
BSX carries more volatility with a beta of 0.57 — expect wider price swings.
AZN is growing revenue faster at 6.7% — sustainability is the question.
AZN generates stronger free cash flow (4.0B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (68/100 vs 62/100), backed by strong 17.7% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?